February 22, 2017 / 1:14 PM / 5 months ago

BRIEF-Ocular Therapeutix NDA resubmission for dextenza accepted by FDA

1 Min Read

Feb 22 (Reuters) - Ocular Therapeutix Inc

* Ocular Therapeutix announces FDA acceptance of NDA resubmission for dextenza for the treatment of ocular pain occurring after ophthalmic surgery

* Ocular Therapeutix Inc - target action date under prescription drug user fee act of July 19, 2017 for potential approval of dextenza Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below